» Articles » PMID: 11751708

Possible Involvement of Rho-kinase in the Pathogenesis of Hypertension in Humans

Overview
Journal Hypertension
Date 2001 Dec 26
PMID 11751708
Citations 107
Authors
Affiliations
Soon will be listed here.
Abstract

Rho-kinase plays an important role in modulating Ca(2+) sensitivity of vascular smooth muscle and has been suggested to be involved in the increased systemic vascular resistance in hypertensive animals. However, it remains to be examined whether this is also the case in patients with essential hypertension. Recently, it has been shown that fasudil is a specific Rho-kinase inhibitor. The aim of this study was to examine whether Rho-kinase is involved in the pathogenesis of hypertension in humans by using this Rho-kinase inhibitor. Studies were performed in hypertensive patients (HT group, n=14) and age-matched normotensive subjects (NT group, n=12). Forearm blood flow was measured by a strain-gauge plethysmograph during intra-arterial infusion of graded doses of fasudil (3.2, 6.4, 12.8, and 25.6 microg/min) or sodium nitroprusside (0.4, 0.8, 1.6, and 3.2 microg/min). Resting forearm vascular resistance was significantly higher in the HT group than in the NT group (22+/-4 versus 17+/-5 U, respectively; P<0.05). The extent of the increase in forearm blood flow evoked by fasudil was significantly greater in the HT group than in the NT group (12.3+/-1.4 versus 6.0+/-0.6 mL. min(-1). 100 mL(-1), respectively; P<0.01). The percent decrease in forearm vascular resistance was significantly greater in the HT group than in the NT group (63.6+/-4.7% versus 29.6+/-3.9%, respectively; P<0.01). By contrast, forearm vasodilator response evoked by sodium nitroprusside was comparable between the 2 groups. These results provide the first evidence that Rho-kinase may be involved in the pathogenesis of the increased peripheral vascular resistance in hypertension in humans.

Citing Articles

Rho-kinase inhibition reduces systolic blood pressure and forearm vascular resistance in healthy older adults: a double-blind, randomized, placebo-controlled pilot study.

Bachman N, Ketelhut N, Blomquist M, Terwoord J Geroscience. 2024; 46(6):6317-6329.

PMID: 38888876 PMC: 11494619. DOI: 10.1007/s11357-024-01240-x.


The Pathogenesis and Impact of Arterial Stiffening in Hypertension: The 2023 John H. Laragh Research Award.

Liu J, Wu J Am J Hypertens. 2024; 37(4):241-247.

PMID: 38214376 PMC: 11484606. DOI: 10.1093/ajh/hpae006.


Suppressed vascular Rho-kinase activation is a protective cardiovascular mechanism in obese female mice.

Barbosa G, Costa R, Awata W, Singh S, Alves J, Bruder-Nascimento A Biosci Rep. 2023; 43(7).

PMID: 37342890 PMC: 10352127. DOI: 10.1042/BSR20230672.


Role of ROCK signaling in virus replication.

Kumar R, Barua S, Tripathi B, Kumar N Virus Res. 2023; 329:199105.

PMID: 36977446 PMC: 10194102. DOI: 10.1016/j.virusres.2023.199105.


ROCK (RhoA/Rho Kinase) Activation in Atrial Fibrillation: Molecular Pathways and Clinical Implications.

Proietti R, Giordani A, Lorenzo C Curr Cardiol Rev. 2023; 19(3):e171122210986.

PMID: 36625201 PMC: 10280999. DOI: 10.2174/1573403X19666221117092951.